Tag Archive for: CytomX

Moderna entered into a collaboration/licensing agreement Thursday with oncology-focused CytomX to discover and develop conditionally activated mRNA therapies for cancer. 

Therapeutics isn’t into exercises in futility. The Bay area-based biopharma company is discontinuing enrollment in two arms of its three-arm Phase II study of praluzatamab ravtansine in patients with triple-negative breast cancer (TNBC) after those studies failed to meet the protocol-defined futility boundary.